차세대 백신 기술 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 기술별, 용도별, 최종 사용자별, 구성 요소별, 디바이스별, 프로세스별, 도입 형태별, 솔루션별

Next-Generation Vaccination Technologies Market is anticipated to expand from $34.2 billion in 2024 to $202.8 billion by 2034, growing at a CAGR of approximately 23.7%. The Next-Generation Vaccination Technologies Market encompasses advanced methods for vaccine development and delivery, including mRNA platforms, viral vectors, and nanoparticle-based systems. These innovations aim to enhance efficacy, safety, and production speed. The market is propelled by increasing demand for rapid response to emerging infectious diseases, personalized immunization strategies, and improved global vaccine access. Key trends include technological advancements in adjuvants, thermostability, and needle-free delivery systems, addressing challenges in distribution and administration.

The Next-Generation Vaccination Technologies Market is poised for substantial growth, driven by advancements in biotechnological innovations and increasing global health awareness. The mRNA vaccine segment leads in performance, attributed to its rapid development capabilities and adaptability to various pathogens. DNA vaccines follow as the second highest performing segment, benefiting from their stability and ease of production. The adjuvant technologies sub-segment within the delivery systems segment is gaining prominence, enhancing vaccine efficacy and immunogenicity. Viral vector vaccines are also experiencing significant traction, particularly for their ability to elicit strong immune responses. Nanoparticle-based delivery systems are emerging as a promising area, offering targeted and controlled vaccine delivery. Innovations in cold chain logistics and storage solutions further support the market's expansion, ensuring vaccine potency and accessibility. The integration of digital health technologies, such as AI-driven analytics and data management platforms, is optimizing vaccine distribution and monitoring, presenting lucrative opportunities for stakeholders.

The Next-Generation Vaccination Technologies Market is characterized by a dynamic distribution of market share, with various companies vying for dominance through strategic pricing and innovative product launches. The competitive landscape is marked by a surge in new entrants, each offering cutting-edge solutions that promise enhanced efficacy and safety. Established players are leveraging their market presence to introduce advanced vaccines, capitalizing on the growing demand for effective immunization options. This competitive drive is further fueled by the need to address emerging infectious diseases, prompting continuous innovation and adaptation. In the realm of competition benchmarking, major pharmaceutical companies are evaluated on their technological advancements and strategic collaborations. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping market entry and expansion. The market is witnessing a shift towards personalized vaccination solutions, driven by advancements in genetic research and biotechnology. The integration of AI and data analytics is enhancing vaccine development processes, positioning companies at the forefront of technological innovation. This landscape presents lucrative opportunities for stakeholders willing to navigate regulatory complexities and invest in R&D.

Geographical Overview:

The Next-Generation Vaccination Technologies Market is witnessing profound growth across several key regions, each exhibiting unique dynamics. North America is at the forefront, driven by robust research and development activities and significant investments in innovative vaccine technologies. The presence of leading biotechnology firms and a strong healthcare infrastructure further propels this growth. In Europe, the market is buoyed by substantial funding for vaccine research and a focus on public health initiatives. The region's commitment to combating infectious diseases enhances its market potential. Asia Pacific is experiencing rapid expansion, fueled by increasing healthcare expenditures and government support for vaccination programs. Emerging economies like China and India are pivotal, with rising demand for advanced vaccines. Latin America and the Middle East & Africa present promising growth pockets. In Latin America, improving healthcare infrastructure and increased awareness drive market expansion. Meanwhile, the Middle East & Africa are investing in vaccination technologies to address public health challenges and bolster healthcare resilience.

Global tariffs and geopolitical tensions are intricately influencing the Next-Generation Vaccination Technologies Market. Japan and South Korea are strategically enhancing domestic R&D capabilities to mitigate reliance on foreign vaccine inputs, while China is accelerating its push for self-sufficiency amidst export controls and tariffs. Taiwan, with its robust biotech sector, remains pivotal yet vulnerable due to geopolitical frictions. The overarching market is witnessing robust growth driven by technological advancements, though supply chain disruptions and trade disputes pose challenges. By 2035, the market is expected to evolve with increased regional collaborations and innovation. Middle East conflicts exacerbate global supply chain vulnerabilities, potentially elevating energy costs and impacting production logistics, thereby necessitating strategic resilience planning across the vaccination technology landscape.

Key Trends and Drivers:

The Next-Generation Vaccination Technologies Market is experiencing robust growth driven by advancements in biotechnology and increased investment in research and development. Key trends include the development of mRNA vaccines, which have gained prominence due to their rapid development and high efficacy. The rise of personalized vaccines tailored to individual genetic profiles is also gaining traction, offering more effective immunization strategies. Another significant trend is the integration of artificial intelligence and machine learning in vaccine development, which accelerates the identification of potential vaccine candidates. Drivers include the urgent need for pandemic preparedness and the global push for more efficient and scalable vaccine production methods. The increasing prevalence of infectious diseases and the demand for innovative vaccination solutions are further propelling market growth. Opportunities abound in emerging markets where vaccination coverage is expanding, driven by government initiatives and international collaborations. Companies investing in next-generation platforms and technologies are well-positioned to capitalize on these emerging opportunities. Moreover, the focus on improving vaccine distribution and storage, particularly in remote areas, is creating avenues for growth. As the world continues to prioritize health security, the Next-Generation Vaccination Technologies Market is poised for sustained expansion.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Component
• 2.7 Key Market Highlights by Device
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Deployment
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Recombinant Vaccines
  • 4.1.2 DNA Vaccines
  • 4.1.3 RNA Vaccines
  • 4.1.4 Subunit Vaccines
  • 4.1.5 Vector-Based Vaccines
  • 4.1.6 Live Attenuated Vaccines
  • 4.1.7 Inactivated Vaccines
  • 4.1.8 Synthetic Vaccines
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Vaccine Formulations
  • 4.2.2 Adjuvants
  • 4.2.3 Vaccine Delivery Devices
  • 4.2.4 Vaccine Packaging
  • 4.2.5 Vaccine Storage Solutions
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Nanoparticle Technology
  • 4.3.2 Virus-Like Particles
  • 4.3.3 Conjugate Technology
  • 4.3.4 Gene Editing
  • 4.3.5 Synthetic Biology
  • 4.3.6 Reverse Vaccinology
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Infectious Diseases
  • 4.4.2 Cancer Vaccines
  • 4.4.3 Allergy Vaccines
  • 4.4.4 Autoimmune Disorders
  • 4.4.5 Neurological Disorders
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Research Institutes
  • 4.5.4 Biopharmaceutical Companies
  • 4.5.5 Government Organizations
• 4.6 Market Size & Forecast by Component (2020-2035)
  • 4.6.1 Antigens
  • 4.6.2 Stabilizers
  • 4.6.3 Preservatives
  • 4.6.4 Adjuvants
• 4.7 Market Size & Forecast by Device (2020-2035)
  • 4.7.1 Needle-Free Injectors
  • 4.7.2 Microneedle Patches
  • 4.7.3 Oral Delivery Systems
  • 4.7.4 Inhalation Devices
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Fermentation
  • 4.8.2 Cell Culture
  • 4.8.3 Purification
  • 4.8.4 Formulation
• 4.9 Market Size & Forecast by Deployment (2020-2035)
  • 4.9.1 On-Premise
  • 4.9.2 Cloud-Based
  • 4.9.3 Hybrid
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Cold Chain Management
  • 4.10.2 Vaccine Tracking Systems

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Component
    • 5.2.1.7 Device
    • 5.2.1.8 Process
    • 5.2.1.9 Deployment
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Component
    • 5.2.2.7 Device
    • 5.2.2.8 Process
    • 5.2.2.9 Deployment
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Component
    • 5.2.3.7 Device
    • 5.2.3.8 Process
    • 5.2.3.9 Deployment
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Component
    • 5.3.1.7 Device
    • 5.3.1.8 Process
    • 5.3.1.9 Deployment
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Component
    • 5.3.2.7 Device
    • 5.3.2.8 Process
    • 5.3.2.9 Deployment
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Component
    • 5.3.3.7 Device
    • 5.3.3.8 Process
    • 5.3.3.9 Deployment
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Component
    • 5.4.1.7 Device
    • 5.4.1.8 Process
    • 5.4.1.9 Deployment
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Component
    • 5.4.2.7 Device
    • 5.4.2.8 Process
    • 5.4.2.9 Deployment
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Component
    • 5.4.3.7 Device
    • 5.4.3.8 Process
    • 5.4.3.9 Deployment
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Component
    • 5.4.4.7 Device
    • 5.4.4.8 Process
    • 5.4.4.9 Deployment
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Component
    • 5.4.5.7 Device
    • 5.4.5.8 Process
    • 5.4.5.9 Deployment
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Component
    • 5.4.6.7 Device
    • 5.4.6.8 Process
    • 5.4.6.9 Deployment
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Component
    • 5.4.7.7 Device
    • 5.4.7.8 Process
    • 5.4.7.9 Deployment
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Component
    • 5.5.1.7 Device
    • 5.5.1.8 Process
    • 5.5.1.9 Deployment
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Component
    • 5.5.2.7 Device
    • 5.5.2.8 Process
    • 5.5.2.9 Deployment
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Component
    • 5.5.3.7 Device
    • 5.5.3.8 Process
    • 5.5.3.9 Deployment
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Component
    • 5.5.4.7 Device
    • 5.5.4.8 Process
    • 5.5.4.9 Deployment
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Component
    • 5.5.5.7 Device
    • 5.5.5.8 Process
    • 5.5.5.9 Deployment
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Component
    • 5.5.6.7 Device
    • 5.5.6.8 Process
    • 5.5.6.9 Deployment
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Component
    • 5.6.1.7 Device
    • 5.6.1.8 Process
    • 5.6.1.9 Deployment
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Component
    • 5.6.2.7 Device
    • 5.6.2.8 Process
    • 5.6.2.9 Deployment
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Component
    • 5.6.3.7 Device
    • 5.6.3.8 Process
    • 5.6.3.9 Deployment
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Component
    • 5.6.4.7 Device
    • 5.6.4.8 Process
    • 5.6.4.9 Deployment
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Component
    • 5.6.5.7 Device
    • 5.6.5.8 Process
    • 5.6.5.9 Deployment
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Cure Vac
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Valneva
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Novavax
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Inovio Pharmaceuticals
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Vaxart
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Geo Vax Labs
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Moderna
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Bio NTech
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Dynavax Technologies
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Bavarian Nordic
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Arcturus Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Immunomic Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Medicago
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Altimmune
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Emergent Bio Solutions
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Gritstone Oncology
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Sorrento Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Translate Bio
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Vir Biotechnology
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Icosavax
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us